ストックスクリーナーアプリを入手
2.19
1.86%
0.04
アフターアワーズ：
2.19
Milestone Pharmaceuticals Inc (MIST) 最新ニュース
How supply chain issues affect Milestone Pharmaceuticals Inc. stockJuly 2025 Earnings & Detailed Earnings Play Alerts - ulpravda.ru
Will Milestone Pharmaceuticals Inc. stock gain from government policies2025 Sector Review & Risk Managed Investment Strategies - ulpravda.ru
Can Milestone Pharmaceuticals Inc. stock continue upward trendJuly 2025 Sentiment & Capital Efficient Trading Techniques - ulpravda.ru
How Milestone Pharmaceuticals Inc. stock benefits from global expansion2025 Growth vs Value & Real-Time Market Sentiment Alerts - ulpravda.ru
Is Milestone Pharmaceuticals Inc. stock a buy in volatile markets2025 Growth vs Value & Short-Term Trading Alerts - ulpravda.ru
Milestone announces acceptance of MAA by EMA for etripamil nasal spray - Yahoo Finance
MIST: HC Wainwright & Co. Reiterates Buy Rating with $8 Price Ta - GuruFocus
Milestone Pharmaceuticals (NASDAQ:MIST) Earns Buy Rating from HC Wainwright - MarketBeat
Milestone Pharmaceuticals Says EMA Accepts Marketing Application for Etripamil Nasal Spray - MarketScreener
Milestone’s PSVT nasal spray MAA accepted by EMA - TipRanks
Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency - The Manila Times
Europe reviews first nose-spray patients could use for sudden PSVT - Stock Titan
Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness - PR Newswire
Simplify Asset Management Inc. Boosts Stock Holdings in Milestone Pharmaceuticals Inc. $MIST - MarketBeat
Milestone Pharmaceuticals Inc. (MIST) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Travel Stocks: How Milestone Pharmaceuticals Inc stock trades before earningsJuly 2025 Intraday Action & Weekly Setup with ROI Potential - moha.gov.vn
Milestone Pharmaceuticals’ Stock Surges as Cardamyst Receives FDA Approval - StocksToTrade
Milestone Pharmaceuticals (MIST) price target increased by 76.00% to 6.73 - MSN
Wyckoff Accumulation Phase Possible in Aveer Foods LimitedVWAP Trading Strategies & Double Or Triple Profits - earlytimes.in
Milestone Pharmaceuticals (MIST) Price Target Increased by 76.00% to 6.73 - Nasdaq
Milestone Pharmaceuticals (NASDAQ:MIST) Raised to "Hold" at Wall Street Zen - MarketBeat
Will Milestone Pharmaceuticals Inc. stock benefit from green energy trendsJuly 2025 Earnings & Fast Moving Stock Trade Plans - Улправда
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Can Milestone Pharmaceuticals Inc. stock deliver strong Q4 earningsChart Signals & Long-Term Growth Portfolio Plans - Улправда
Milestone Pharmaceuticals shares rally after FDA greenlights first at-home PSVT nasal therapy - MSN
Aug Intraday: Will Milestone Pharmaceuticals Inc. stock gain from lower inflationWeekly Market Outlook & Entry and Exit Point Strategies - Улправда
Can Milestone Pharmaceuticals Inc. stock deliver consistent earnings growth2025 Trading Recap & Real-Time Stock Entry Alerts - Улправда
Best Penny Stocks To Watch TodayDecember 15th - MarketBeat
Aptar’s Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT) - Business Wire
What is HC Wainwright's Estimate for MIST FY2026 Earnings? - MarketBeat
Wells Fargo maintains Milestone Pharmaceuticals (MIST) overweight recommendation - MSN
Wells Fargo Maintains Milestone Pharmaceuticals (MIST) Overweight Recommendation - Nasdaq
Traders Purchase High Volume of Call Options on Milestone Pharmaceuticals (NASDAQ:MIST) - MarketBeat
Wells Fargo Raises Price Target for Milestone Pharmaceuticals (M - GuruFocus
Milestone Pharmaceuticals upgraded to Buy at TD Cowen after Cardamyst approval - Yahoo Finance
Milestone Pharmaceuticals (MIST): Taking Stock of Valuation After FDA Approval of CARDAMYST Nasal Spray - Yahoo Finance
Milestone Pharmaceuticals Poised for Success with Cardamyst Approval and Strong Market Potential - TipRanks
Milestone Pharmaceuticals: Cardamyst Beat Placebo, But The Commercial Bar Is Higher (MIST) - Seeking Alpha
Milestone Embarks On ‘Show-Me’ Story With Cardamyst Launch - Citeline News & Insights
HC Wainwright & Co. Maintains Milestone Pharmaceuticals (MIST) Buy Recommendation - Nasdaq
Milestone Pharmaceuticals stock rating upgraded by TD Cowen to Buy on FDA approval - Investing.com Canada
MIST Stock Upgraded to 'Buy' by TD Cowen with New Price Target | - GuruFocus
MIST: Analyst Raises Price Target by 60% Amid Positive Outlook | - GuruFocus
Milestone Pharmaceuticals (MIST) Stock Jumps 35% on Groundbreaking FDA Approval - parameter.io
Milestone Pharmaceuticals (NASDAQ:MIST) Raised to Buy at TD Cowen - MarketBeat
Milestone’s long regulatory road ends in approval for Cardamyst - PharmaLive
Milestone Pharmaceuticals Inc. (MIST) Discusses FDA Approval and Clinical Insights for CARDAMYST Nasal Spray in PSVT TreatmentSlideshow (NASDAQ:MIST) 2025-12-15 - Seeking Alpha
MIST stock soars pre-market after FDA approves first commercial product – retail remains bullish, dismisses 'sell the news' concerns - MSN
Milestone Pharmaceuticals Gains FDA Approval for CARDAMYST - TipRanks
Milestone Wins FDA Approval For First Self-Use Nasal Spray For Sudden Fast Heartbeats - Sahm
Why Is Milestone Pharmaceuticals Stock Skyrocketing Monday?Milestone Pharmaceuticals (NASDAQ:MIST) - Benzinga
Milestone Pharmaceuticals (MIST) Stock: Wild Price Swings Follow FDA Approval Decision - Blockonomi
[8-K] Milestone Pharmaceuticals Inc. Reports Material Event | MIST SEC FilingForm 8-K - Stock Titan
Milestone’s Long Regulatory Road Ends in Approval for Cardamyst - BioSpace
MIST Stock Soars Pre-Market After FDA Approves First Commercial Product – Retail Remains Bullish, Dismisses ‘Sell The News’ Concerns - Stocktwits
Milestone Pharma gains on FDA approval of nasal spray for patients with heart condition - TradingView — Track All Markets
Milestone wins first-ever FDA approval with green light for heart arrhythmia nasal spray - Fierce Pharma
Milestone stock soars after FDA approves first self-administered PSVT spray - Investing.com India
Milestone Pharmaceuticals (MIST) Stock: FDA Approval of CARDAMYST, Launch Timeline, and Analyst Forecasts (Dec. 15, 2025) - ts2.tech
0.80%
4.56%
大文字化:
|
ボリューム (24 時間):